Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides caloric support and helps correct hypoglycemia. Sodium chloride is an electrolyte that maintains osmotic balance and fluid volume.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Fluid and electrolyte replacement,Treatment of dehydration,Caloric supplementation in parenteral nutrition
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous infusion; dosage depends on fluid and electrolyte requirements. Typical maintenance: 75-150 m L/kg/day for adults, administered as continuous infusion.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Not applicable for dextrose as it is rapidly metabolized; plasma glucose half-life is approximately 1.7-2.0 hours after IV infusion but highly variable depending on metabolic demand and insulin activity. For sodium chloride, ions are continuously regulated by renal handling; no traditional half-life.
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Dextrose is metabolized via glycolysis and the citric acid cycle. Sodium chloride is not metabolized; it is excreted renally.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Dextrose is metabolized to CO2 and water via glycolysis and the Krebs cycle; negligible renal excretion (<5%). Sodium chloride is excreted renally with sodium and chloride ions freely filtered and variably reabsorbed (99% reabsorption under normal conditions, but excretion increases with excess intake).
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Dextrose: negligible (<1%); not protein-bound. Sodium and chloride ions: negligible (<1%); are free ions in plasma.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Dextrose: approximately 0.25-0.4 L/kg, reflecting distribution primarily into extracellular fluid and cells. Sodium chloride: sodium distributes mainly in extracellular fluid (Vd ~0.2 L/kg for sodium), chloride follows sodium distribution.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Intravenous: 100% (complete bioavailability). No other relevant routes; oral dextrose is absorbed but formulation is for IV use only.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
GFR >= 50 m L/min: no adjustment; GFR 30-49 m L/min: reduce total volume by 20-30% or use with caution; GFR <30 m L/min: avoid use due to risk of fluid overload and hypernatremia unless carefully monitored.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
Child-Pugh A: no adjustment; Child-Pugh B: monitor for fluid overload and electrolyte disturbances; Child-Pugh C: use with caution, reduce infusion rate and volume, may need diuretic therapy.
No dosage adjustment required for hepatic impairment.
Intravenous infusion: neonates: 60-120 m L/kg/day; infants: 100-120 m L/kg/day; children: 75-100 m L/kg/day; adjust based on clinical status and serum electrolytes.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Elderly patients may require reduced total volume and slower infusion rate due to decreased renal function and increased risk of fluid overload; monitor serum sodium, potassium, and fluid balance closely.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
None
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Risk of hyperglycemia in patients with diabetes mellitus,Risk of fluid overload in patients with heart failure or renal impairment,Electrolyte imbalances with prolonged use,Do not administer if solution contains particulate matter or is discolored
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hyperglycemia,Hypernatremia,Fluid overload,Known hypersensitivity to any component
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No food interactions. May affect glucose control in diabetics; maintain consistent carbohydrate intake.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Dextrose and sodium chloride are physiologic substances. No teratogenic risk has been identified at standard infusion rates. First trimester: No known risk. Second trimester: No known risk. Third trimester: Use caution to avoid fluid/electrolyte imbalance, which may affect fetal homeostasis.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Both dextrose and sodium chloride are normal constituents of breast milk. Exogenous administration does not significantly alter milk composition. M/P ratio: Not applicable (endogenous substances). Compatible with breastfeeding.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering electrolyte and glucose homeostasis. No standard dose adjustment required for maintenance fluids; however, infusion rate should be tailored to maternal volume status, serum sodium, and glucose levels. Monitor for hyperglycemia in gestational diabetes.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Used for maintenance fluid therapy; monitor for fluid overload in patients with CHF or renal impairment. Check serum glucose in diabetics as dextrose may cause hyperglycemia. Avoid in resuscitation due to hypotonicity.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
Report any swelling of hands, feet, or shortness of breath immediately.,If diabetic, monitor blood glucose closely.,This solution provides hydration and electrolytes; do not adjust infusion rate yourself.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides caloric support and helps correct hypoglycemia. Sodium chloride is an electrolyte that maintains osmotic balance and fluid volume.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is: Intravenous infusion; dosage depends on fluid and electrolyte requirements. Typical maintenance: 75-150 m L/kg/day for adults, administered as continuous infusion.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER is classified as Category A/B. Dextrose and sodium chloride are physiologic substances. No teratogenic risk has been identified at standard infusion rates. First trimester: No known risk. Second trimester: No kn. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.